{"preliminary_commentary":{"by_channel":{"x_thread":27,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02951767\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["atezolizumab"]],"indication":"locally advanced or metastatic urothelial bladder cancer","name":"IMvigor210","nct_id":"NCT02951767","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imvigor210-nct02951767. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with advanced disease who are treatment-naive for advanced urothelial carcinoma and cisplatin ineligible will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.","label":"Cohort 1: Treatment-naive Cisplatin Ineligible Participants","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-02-28","type":"ACTUAL"},"conditions":["Bladder Cancer"],"enrollment":{"count":119,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL3280A","Tecentriq"],"type":"DRUG"}],"last_update":"2024-03-28","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2016-07-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to RECIST v1.1","timeFrame":"Baseline until confirmed disease progression or death, whichever occurred first (assessed at every 9 weeks for the first 12 months, thereafter every 12 weeks until data cutoff date 04 July 2016, up to maximum length of follow-up of 23.52 months)"}],"references":[{"citation":"Szabados B, Ponz-Sarvise M, Machado R, Saldana D, Kadel EE, Banchereau R, Bouquet F, Garmhausen M, Powles T, Schroder C; imCORE Working Group of Early Career Investigators (imFLAME). Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI). Clin Cancer Res. 2022 Sep 15;28(18):4083-4091. doi: 10.1158/1078-0432.CCR-22-0200.","pmid":"35877091","type":"DERIVED"},{"citation":"Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thastrom A, Liu S, Shi L, Leppert JT. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. Eur Urol Oncol. 2019 Feb;2(1):12-20. doi: 10.1016/j.euo.2018.07.003. Epub 2018 Aug 4.","pmid":"30929841","type":"DERIVED"}],"start_date":{"date":"2014-05-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)","url":"https://clinicaltrials.gov/study/NCT02951767"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imvigor210-nct02951767"}